Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Elopag 50 mg Tablets (Eltrombopag)
Eltrombopag 50mg tablets – Everest Pharmaceuticals Ltd.
Approved for adults and children with chronic immune thrombocytopenia (ITP) with insufficient response to other treatments, severe aplastic anemia (often combined with immunosuppressive therapy), and thrombocytopenia associated with chronic hepatitis C to enable interferon-based treatment.
- Clinical outcomes at a glance
~80%
Of chronic ITP patients achieved platelet counts ≥50,000 (RAISE trial)
~40%
Overall hematologic response in severe aplastic anemia (NIH studies)
Once
Daily oral dosing — taken on an empty stomach
TPO-RA
Thrombopoietin receptor agonist — stimulates platelet production
- Am I a candidate? — Take Decesion
1
Confirm diagnosis and prior treatment history
For ITP, typically considered after corticosteroids, IVIG, or other first-line treatments haven’t provided enough benefit; for severe aplastic anemia, used alongside or after immunosuppressive therapy.
2
Baseline liver function and platelet count testing
Liver enzymes (ALT, AST, bilirubin) and complete blood count must be checked before starting and monitored throughout treatment.
3
Review clotting risk factors with your physician
History of blood clots, certain cancers, or conditions affecting blood vessel health affect the risk-benefit discussion, since this medication increases platelet production.
4
Discuss your goals of care
Weigh bleeding-risk reduction and avoiding procedures like splenectomy against monitoring requirements and the strict dietary/medication timing rules this drug requires.
Important safety information — boxed warning: Eltrombopag carries a boxed warning for hepatotoxicity, including liver injury that can be severe and, in rare cases, fatal. Liver function tests are required before starting treatment and regularly throughout. It also carries risks of increased blood clot formation (thrombosis/thromboembolism), and in certain blood disorders, a risk of disease progression to more advanced forms.
- common side effects to know
- Nausea
- Diarrhea
- Headache
- Mild liver enzyme elevation
- Severe liver injury
- Blood clots (DVT / PE / stroke)
- Trust & expertise
- FDA Approved 2008
- EMA Approved 2010
- ASH ITP Guidelines
- ASH ITP Guidelines
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Eltrombopag has given many chronic ITP patients a way to raise platelet counts and reduce bleeding risk without surgery. The trade-off is a strict daily routine — timing around food and other medications matters a lot here — plus consistent liver and clotting risk monitoring. Patients who understand the routine tend to do well on it.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
Here are key questions to bring to your hematologist about starting eltrombopag — the liver monitoring and timing/dietary rules are the two areas that deserve the most attention.
Before confirming eltrombopag as your treatment
- Which prior treatments have I tried (corticosteroids, IVIG, other therapies), and is eltrombopag being considered because those weren’t enough, or because of side effects from them?
- What’s my target platelet count, and how will we know if this is working?
- Are there alternatives I should know about — like another thrombopoietin receptor agonist (romiplostim), or non-medication options such as splenectomy?
About the boxed warning — liver injury
- Do I need baseline liver function tests before starting, and how often will they be repeated afterward?
- What symptoms of liver problems — yellowing of skin/eyes, dark urine, severe fatigue, abdominal pain — should prompt me to call you immediately versus go to the ER?
- Do I have any history of liver disease (including hepatitis) that affects how this medication will be dosed or monitored?
About blood clot risk
- Do I have any personal or family history of blood clots, stroke, or heart attack that’s relevant here?
- If my platelet count rises significantly, does my clot risk change — and would my dose be adjusted?
- What symptoms of a blood clot (leg swelling, pain, sudden shortness of breath, chest pain) need immediate attention?
About the dosing and dietary rules — this is the part that trips people up
- What does “empty stomach” mean in practice — how many hours before or after meals should I take this?
- Which foods, supplements, or medications do I need to space out from my dose, and by how long? (Calcium-rich foods, dairy, antacids, and mineral supplements like iron, calcium, magnesium, or zinc commonly interfere with absorption.)
- If I take other medications at specific times of day, how do we build a schedule that works around this?
- What happens if I accidentally take it with food or close to one of these substances — does it just reduce effectiveness, or is there a safety concern?
About monitoring overall
- How often will I need blood counts checked, especially in the first few months?
- Is there a risk of my platelet count going too high, and what would we do about that?
- For severe aplastic anemia specifically — will this be combined with other treatments, and how do we track whether all the blood cell lines (red cells, white cells, platelets) are responding?
About my specific situation
- If I’m of childbearing potential, what precautions are needed?
- Does my ethnicity affect dosing — I’ve heard some populations may need different starting doses for this medication?
- How does this interact with my other current medications, beyond the timing-related ones?
About the longer road
- If this doesn’t raise my platelet counts enough, what’s the next step?
- If it works well, is this a long-term medication, or could we eventually taper or stop?
- Are there patient assistance programs through the manufacturer if cost is a concern?
A practical tip: Because the timing rules are unusually strict for this medication compared to most oral drugs, it’s worth asking your hematologist or pharmacist to help you build a literal daily schedule — including a buffer window around your dose — rather than trying to remember the rules in the abstract.
compare with other therapies
Eltrombopag and romiplostim are both thrombopoietin receptor agonists (TPO-RAs) approved for chronic ITP after first-line treatments haven’t worked well enough — and unlike some of our earlier comparisons, they’re considered broadly comparable in efficacy, with the decision often coming down to administration route and individual risk factors rather than one being clearly superior.
How they’re given — the biggest practical difference
| Eltrombopag (Promacta/Revolade) | Romiplostim (Nplate) | |
|---|---|---|
| Form | Oral tablet | Subcutaneous injection |
| Frequency | Once daily | Once weekly |
| Where administered | At home, self-administered | Typically in clinic initially; some patients learn self-injection |
| Drug type | Small molecule (non-peptide) | Peptibody (peptide fused to antibody fragment) |
| Binding site | Different site on TPO receptor than natural TPO | Mimics natural thrombopoietin directly |
This is often the deciding factor for many patients: a daily pill with strict dietary timing rules versus a weekly injection that requires more clinic visits, at least initially.
Efficacy
Both drugs have shown response rates in the range of roughly 70–80% of patients achieving and maintaining platelet counts above target thresholds in their respective pivotal trials. Head-to-head comparisons haven’t shown one to be consistently superior to the other for raising platelet counts or reducing bleeding episodes — efficacy is generally considered similar between the two.
Safety profile differences
| Eltrombopag | Romiplostim | |
|---|---|---|
| Boxed warning | Hepatotoxicity (liver injury) | None — but carries warnings for bone marrow fibrosis and thrombotic risk |
| Liver monitoring | Required, regularly | Not a primary focus |
| Bone marrow reticulin fiber increase | Possible | Possible — a shared class concern |
| Blood clot risk | Increased | Increased |
| Rebound thrombocytopenia after stopping | Yes | Yes |
| Dietary/medication interactions | Significant (calcium, antacids, dairy) | None — injection bypasses GI absorption entirely |
The dietary interaction issue essentially disappears with romiplostim, since it’s injected rather than absorbed through the gut — this can be a meaningful advantage for patients who take a lot of other medications or have dietary patterns that conflict with eltrombopag’s timing rules.
Practical considerations that often guide the choice
- Needle aversion or injection comfort — a strong factor for patients choosing eltrombopag over romiplostim
- Adherence with complex daily routines — patients who struggle with the empty-stomach/spacing rules for eltrombopag may do better with a once-weekly injection
- Clinic access — romiplostim’s initial weekly clinic visits (for dose-finding) may be a barrier for patients who live far from their treatment center, though many transition to home self-injection once stable
- Liver health — a patient with existing liver concerns might be steered toward romiplostim to avoid the added hepatotoxicity monitoring burden
- Cost and insurance coverage — both are specialty-tier medications, and coverage/cost can vary significantly by insurer and region, sometimes becoming a deciding factor
A third option worth knowing about
Avatrombopag (Doptelet) is a newer oral TPO-RA, also approved for chronic ITP, that does not have the same dietary restrictions as eltrombopag — it can be taken with food. If the timing rules are a major concern with eltrombopag, this may be worth asking about as well.
Bottom line
Both drugs work through the same general mechanism with broadly similar effectiveness — the choice tends to hinge on whether a daily pill with dietary timing constraints (eltrombopag) or a weekly injection without those constraints (romiplostim) fits better with your lifestyle, other medications, and any liver health considerations. This is very much a “which trade-offs work for you” conversation rather than one drug being medically preferable to the other in most cases
How does testing work
Polyvalent cations (positively charged metal ions with multiple charges, like calcium, iron, magnesium, and aluminum) physically bind to eltrombopag in your gut before it can be absorbed — and this binding can reduce the amount that gets into your bloodstream by roughly 50% or more.
Here’s the mechanism in more detail:
Chelation — the core issue
Eltrombopag has a chemical structure that readily forms tight complexes with metal ions through a process called chelation — essentially, the drug molecule “grabs onto” these ions and forms a larger, poorly absorbed complex. Once chelated, the eltrombopag-mineral complex is too large and too insoluble to cross into the bloodstream effectively, so it passes through the digestive system largely unused.
This isn’t a side effect or toxicity concern — it’s purely a bioavailability problem. The drug becomes much less effective at the dose you’re taking, not unsafe.
What specifically interferes
- Calcium — found in dairy products (milk, cheese, yogurt), calcium-fortified foods (some juices, cereals), and calcium supplements
- Antacids — particularly those containing aluminum or magnesium hydroxide (common in many over-the-counter antacid brands)
- Iron supplements — including multivitamins containing iron
- Other mineral supplements — zinc, selenium, and similar polyvalent cation-containing products
Why “empty stomach” matters separately
Beyond the mineral-binding issue, food in general — even food without these specific minerals — can reduce eltrombopag absorption. This is why the standard guidance is to take it at least 2 hours before or 4 hours after any of these substances, and ideally on an empty stomach or with a meal low in calcium.
What this looks like practically
A common approach is:
- Take eltrombopag first thing in the morning before breakfast, or
- Take it at bedtime, several hours after your last meal and any calcium-containing foods or supplements
If you take a multivitamin or calcium supplement, that needs to be scheduled at a clearly separated time — for example, eltrombopag at bedtime and supplements at breakfast, with several hours of separation.
The bigger picture
This is a good example of why the “strict timing rules” aren’t arbitrary — they’re rooted in basic pharmacology (chelation chemistry), and getting them wrong doesn’t cause harm directly, but it can mean your platelet counts don’t respond as expected, which might lead your doctor to think the dose needs increasing when really the issue is absorption timing.
If you’re someone who relies on dairy in your diet, takes a daily multivitamin, or uses antacids regularly (for reflux, for example), this is worth flagging early with your hematologist or pharmacist so you can build a schedule that actually works — rather than discovering after a few weeks that your platelet counts aren’t responding as hoped.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
